title: Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients.
abstract: The purpose of this study was to assess the prevalence of dyslipoproteinemia and to analyze the clinical variables that are associated with it in a sample of premenopausal systemic lupus erythematosus (SLE) patients. We studied 53 premenopausal (34.5 y) SLE outpatients and 45 controls. Clinical variables studied included patient age, weight, height, body mass index (BMI), age at disease onset, disease duration, clinical activity of SLE, renal involvement and drug therapy. Total cholesterol (TC), high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), and triglycerides were measured using standard enzymatic techniques. Apolipoproteins (apo) A-I and B were determined by radial immunodiffusion. Twenty-nine patients (55%) and 14 controls (30%) had dyslipoproteinemia. An increase in TC, triglycerides, HDL3-C, apo A-I and apo B, and a decrease in HDL2-C and HDL-C/TC index was found in SLE patients in comparison with controls. TC (P = 0.007), apo B (P = 0.02), LDL-C (P = 0.03) and triglycerides (P = 0.0001) were significantly correlated with proteinuria. Patients on prednisone therapy had higher triglycerides levels (P = 0.03) than untreated patients. TC (P = 0.01), LDL-C (P = 0.006) and triglycerides (P = 0.04) were also correlated with the dose of prednisone. Dyslipoproteinemia is a common feature in adult SLE premenopausal patients which is characterized by an increase in TC, triglycerides and apo B, and an abnormal distribution of HDL subclasses. Corticosteroid therapy and proteinuria are the best predictors of dyslipoproteinemia in these patients.
authors.affiliation: Internal Medicine Service, Bellvitge Hospital, Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Formiga
authors.forename: J F
authors.initials: JF
authors.lastname: Meco
authors.forename: X
authors.initials: X
authors.lastname: Pinto
authors.forename: J
authors.initials: J
authors.lastname: Jacob
authors.forename: I
authors.initials: I
authors.lastname: Moga
authors.forename: R
authors.initials: R
authors.lastname: Pujol
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000453:epidemiology*; D008055:Lipids / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology*; D011239:Prednisolone / Q000627:therapeutic use; D017697:Premenopause / Q000097:blood; D015995:Prevalence; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005938:Glucocorticoids; D008055:Lipids; D014280:Triglycerides; D011239:Prednisolone